Biochemical markers for assessment of calcium economy and bone metabolism: Application in clinical trials from pharmaceutical agents to nutritional products

Nutrition Research Reviews

Volumn 39, Issue 11, 2014, Pages

  Bonjour, Jean Philippe ^a   Kohrt, Wendy ^b   Levasseur, Régis ^c   Warren, Michelle ^d   Whiting, Susan ^e   Kraenzlin, Marius ^f  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF COLORADO   (United States)

^c ANGERS UNIVERSITY HOSPITAL   (France)

^d Department of Medicine   (United States)

^e UNIVERSITY OF SASKATCHEWAN   (Canada)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Bone turnover markers; Bone related hormones; Clinical nutrition trials

Indexed keywords

25 HYDROXYVITAMIN D; ANABOLIC AGENT; BIOCHEMICAL MARKER; CALCIUM; CALCIUM ION; NEW DRUG; PARATHYROID HORMONE; PHOSPHATE; SOMATOMEDIN C; VITAMIN D; NUTRACEUTICAL; BIOLOGICAL MARKER; BONE DENSITY CONSERVATION AGENT;

ANOREXIA NERVOSA; BONE CELL; BONE DENSITY; BONE DEVELOPMENT; BONE METABOLISM; BONE REMODELING; BONE TURNOVER; CELL METABOLISM; CLINICAL RESEARCH; COMPARATIVE EFFECTIVENESS; DIET SUPPLEMENTATION; DIET THERAPY; DIETARY INTAKE; EATING DISORDER; EVIDENCE BASED PRACTICE; FOOD INTAKE; FRAGILITY FRACTURE; HUMAN; MEDICAL ETHICS; NONHUMAN; OBESITY; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PATIENT MONITORING; POPULATION RISK; POSTMENOPAUSE; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SAMPLE SIZE; STUDY DESIGN; VITAMIN BLOOD LEVEL; WEIGHT CHANGE; WEIGHT REDUCTION; CLINICAL TRIAL (TOPIC); NUTRIENT; BLOOD; BONE; DIET; DRUG EFFECTS; METABOLISM; NUTRITIONAL STATUS;

BIOMARKERS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CLINICAL TRIALS AS TOPIC; DIET; HUMANS; NUTRITIONAL STATUS; OSTEOPOROSIS;

EID: 84921844082     PISSN: 09544224     EISSN: 14752700     Source Type: Journal    
DOI: 10.1017/S0954422414000183     Document Type: Review

References (168)

1. Rizzoli R & Bonjour JP (2006) Physiology of calcium and phosphate homeostasis. In Dynamics of Bone and Cartilage Metabolism: Principles and Clinical Applications, 2nd ed., pp. 345-360 [MJ Seibel, SP Robins and JP Bilezikian, editors]. San Diego: Academic Press.
2. Lensmeyer GL, Binkley NC & Drezner MK (2006) New horizons for assessment of vitamin D status in man. In Dynamics of Bone and Cartilage Metabolism: Principles and Clinical Applications, 2nd ed., pp. 513-527 [M Seibel, SP Robins and JP Bilezikian, editors]. San Diego: Academic Press.
3. Souberbielle JC, Friedlander G & Cormier C (2006) Practical considerations in PTH testing. Clin Chim Acta 366, 81-89.
4. Jüppner H & Fulehan GE-H (2006) Measurement of parathyroid hormone. In Dynamics of Bone and Cartilage Metabolism: Principles and Clinical Applications, 2nd ed., pp. 507-512 [M Seibel, SP Robins and J.P. Bilezikian, editors]. San Diego: Academic Press.
5. Hjortebjerg R & Frystyk J (2013) Determination of IGFs and their binding proteins. Best Pract Res Clin Endocrinol Metab 27, 771-781.
6. Kraenzlin ME & Seibel MJ (2006) Measurements of biochemical markers of bone resorption. In Dynamic Bone and Cartilage Metabolism: Principles and Clinical Applications, 2nd ed., pp. 541-563 [MJ Seibel, SP Robins and J.P. Bilezikian, editors]. San Diego: Academic Press.
7. Lee J & Vasikaran S (2012) Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis. Ann Lab Med 32, 105-112.
8. Naylor K & Eastell R (2012) Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol 8, 379-389.
9. Vasikaran S, Cooper C, Eastell R, et al. (2011) International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med 49, 1271-1274.
10. World Health Organization (2007) Assessment of Osteoporosis at the Primary Health Care Level. Report of a WHO Scientific Group. Geneva: WHO.
11. Harvey N, Dennison E & Cooper C (2008) Epidemiology of osteoporotic fractures. In Primer of the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th ed., pp. 198-203 [CJ Rosen, JE Compston and J.B. Lian, editors]. Washington, DC: The American Society of Bone and Mineral Metabolism.
12. Hopkins RB, Goeree R, Pullenayegum E, et al. (2011) The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women. BMC Musculoskelet Disord 12, 209.
13. Murad MH, Drake MT, Mullan RJ, et al. (2012) Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 97, 1871-1880.
14. Downey TW, Foltz SH, Boccuzzi SJ, et al. (2006) Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J 99, 570-575.
15. Rossini M, Bianchi G, Di Munno O, et al. (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17, 914-921.
16. Silverman S & Gold DT (2010) Compliance and persistence with osteoporosis medications: a critical review of the literature. Rev Endocr Metab Disord 11, 275-280.
17. Schousboe JT (2013) Adherence with medications used to treat osteoporosis: behavioral insights. Curr Osteoporos Rep 11, 21-29.
18. Blumberg J, Heaney RP, Huncharek M, et al. (2010) Evidence-based criteria in the nutritional context. Nutr Rev 68, 478-484.
19. Heaney RP (2008) Nutrients, endpoints, and the problem of proof. J Nutr 138, 1591-1595.
20. Guyatt GH (1998) Evidence-based management of patients with osteoporosis. J Clin Densitom 1, 395-402.
21. Harris RP, Helfand M, Woolf SH, et al. (2001) Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 20, 21-35.
22. Woolf SH, DiGuiseppi CG, Atkins D, et al. (1996) Developing evidence-based clinical practice guidelines: lessons learned by the US Preventive Services Task Force. Annu Rev Public Health 17, 511-538.
23. Biesalski HK, Aggett PJ, Anton R, et al. (2011) 26th Hohenheim Consensus Conference, September 11, 2010. Scientific substantiation of health claims: evidence-based nutrition. Nutrition 27, S1-S20.
24. Fenton TR & Fenton CJ (2011) Nutrition science mustn't accept a lower level of evidence. Nutr Rev 69, 413-414.
25. Heaney RP & Blumberg J (2011) Author reply: nutrition science mustn't accept a lower level of evidence. Nutr Rev 69, 415-416.
26. Woodside JV, Koletzko BV, Patterson CC, et al. (2013) Scientific standards for human intervention trials evaluating health benefits of foods, and their application to infants, children and adolescents. World Rev Nutr Diet 108, 18-31.
27. Bonjour JP, Ammann P & Rizzoli R (1999) Importance of preclinical studies in the development of drugs for treatment of osteoporosis: a review related to the 1998 WHO guidelines. Osteoporos Int 9, 379-393.
28. Bruyere O, Rizzoli R, Coxam V, et al. (2012) Assessment of health claims in the field of bone: a view of the Group for the Respect of Ethics and Excellence in Science (GREES). Osteoporos Int 23, 193-199.
29. Prentice A, Bonjour JP, Branca F, et al. (2003) PASSCLAIM - bone health and osteoporosis. Eur J Nutr 42, Suppl. 1, I28-I49.
30. Sibai T, Morgan EF & Einhorn TA (2011) Anabolic agents and bone quality. Clin Orthop Relat Res 469, 2215-2224.
31. Syed FA & Melim T (2011) Rodent models of aging bone: an update. Curr Osteoporos Rep 9, 219-228.
32. Kanis JA, McCloskey EV, Johansson H, et al. (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24, 23-57.
33. Schuit SCE, van der Klift M, Weel AEAM, et al. (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34, 195-202.
34. Sornay-Rendu E, Munoz F, Garnero P, et al. (2005) Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 20, 1813-1819.
35. Siris ES, Chen YT, Abbott TA, et al. (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164, 1108-1112.
36. Boutroy S, Bouxsein ML, Munoz F, et al. (2005) In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab 90, 6508-6515.
37. Eastell R, Arnold A, Brandi ML, et al. (2009) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94, 340-350.
38. Tannenbaum C, Clark J, Schwartzman K, et al. (2002) Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 87, 4431-4437.
39. Lips P, Duong T, Oleksik A, et al. (2001) A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab 86, 1212-1221.
40. Boonen S, Bischoff-Ferrari HA, Cooper C, et al. (2006) Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: a review of the evidence. Calcif Tissue Int 78, 257-270.
41. Tang BM, Eslick GD, Nowson C, et al. (2007) Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 370, 657-666.
42. Tenta R, Moschonis G, Koutsilieris M, et al. (2011) Calcium and vitamin D supplementation through fortified dairy products counterbalances seasonal variations of bone metabolism indices: the Postmenopausal Health Study. Eur J Nutr 50, 341-349.
43. Kanellakis S, Moschonis G, Tenta R, et al. (2012) Changes in parameters of bone metabolism in postmenopausal women following a 12-month intervention period using dairy products enriched with calcium, vitamin D, and phylloquinone (vitamin K1) or menaquinone-7 (vitamin K2): the Postmenopausal Health Study II. Calcif Tissue Int 90, 251-262.
44. Cavalier E, Rozet E, Gadisseur R, et al. (2010) Measurement uncertainty of 25-OH vitamin D determination with different commercially available kits: impact on the clinical cut offs. Osteoporos Int 21, 1047-1051.
45. Eddington H, Hudson JE, Oliver RL, et al. (2013) Variability in parathyroid hormone assays confounds clinical practice in chronic kidney disease patients. Ann Clin Biochem 51, 228-236.
46. Mason RS (2010) Vitamin D: a hormone for all seasons. Climacteric 14, 197-203.
47. Ross AC, Manson JE, Abrams SA, et al. (2011) The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 96, 53-58.
48. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96, 1911-1930.
49. Ginde AA, Wolfe P, Camargo CA Jr, et al. (2012) Defining vitamin D status by secondary hyperparathyroidism in the U.S. population. J Endocrinol Invest 35, 42-48.
50. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. (2012) Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab 97, 1153-1158.
51. Rosen CJ, Abrams SA, Aloia JF, et al. (2012) IOM committee members respond to Endocrine Society vitamin D guideline. J Clin Endocrinol Metab 97, 1146-1152.
52. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. (2005) Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 293, 2257-2264.
53. Boonen S, Lips P, Bouillon R, et al. (2007) Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 92, 1415-1423.
54. Bischoff-Ferrari HA (2010) Vitamin D and fracture prevention. Endocrinol Metab Clin North Am 39, 347-353.
55. Warriner AH & Saag KG (2013) Osteoporosis diagnosis and medical treatment. Orthop Clinics North Am 44, 125-135.
56. Macdonald HM, Wood AD, Aucott LS, et al. (2013) Hip bone loss is attenuated with 1000 IU but not 400 IU daily vitamin D3: a 1-year double-blind RCT in postmenopausal women. J Bone Miner Res 28, 2202-2213.
57. Clemmons DR (2011) Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem 57, 555-559.
58. Schürch MA, Rizzoli R, Slosman D, et al. (1998) Protein supplements increase serum insulin-like growth factor-I levels and attenuate proximal femur bone loss in patients with recent hip fracture. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128, 801-809.
59. Thissen JP, Ketelslegers JM & Underwood LE (1994) Nutritional regulation of the insulin-like growth factors. Endocr Rev 15, 80-101.
60. Bonjour JP, Ammann P, Chevalley T, et al (2003) Nutritional aspects of bone growth: an overview. In Nutritional Aspects of Bone Health, pp. 111-127 [S New and JP Bonjour, editors]. Cambridge, UK: The Royal Society of Chemistry.
61. Giustina A, Mazziotti G & Canalis E (2008) Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 29, 535-559.
62. Bonjour JP, Schürch MA, Chevalley T, et al. (1997) Protein intake, IGF-1 and osteoporosis. Osteoporos Int 7, Suppl. 3, S36-S42.
63. Perrini S, Laviola L, Carreira MC, et al. (2010) The GH/IGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis. J Endocrinol 205, 201-210.
64. Sugimoto T, Nishiyama K, Kuribayashi F, et al. (1997) Serum levels of insulin-like growth factor (IGF) I, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. J Bone Miner Res 12, 1272-1279.
65. Garnero P, Sornay-Rendu E & Delmas PD (2000) Low serum IGF-1 and occurrence of osteoporotic fractures in postmenopausal women. Lancet 355, 898-899.
66. Vasikaran S, Eastell R, Bruyere O, et al. (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22, 391-420.
67. Henriksen K, Tanko LB, Qvist P, et al. (2007) Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int 18, 681-685.
68. Halleen J, Hentunen TA, Karp M, et al. (1998) Characterization of serum tartrate-resistant acid phosphatase and development of a direct two-site immunoassay. J Bone Miner Res 13, 683-687.
69. Halleen J, Alatalo SL, Janckila AJ, et al. (2001) Serum tartrate- resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem 47, 597-600.
70. Kraenzlin ME, Lau KHW, Liang L, et al. (1990) Development of an immunoassay for human serum osteoclastic tartrateresistant acid phosphatase. J Clin Endocrinol Metab 71, 442-451.
71. Hannon R, Clowes J, Eagleton AC, et al. (2004) Clinical performance of immunoreative tartrate resistent acid phosphatase isoform 5b as a marker of bone resorption. Bone 34, 187-194.
72. Garnero P, Borel O & Delmas P (2001) Evaluation of a fully automated serum assay for C-terminal cross-linking teleopeptide of type I collagen in osteoporosis. Clin Chem 47, 694-702.
73. Garnero P, Sornay-Rendu E, Chapuy MC, et al. (1996) Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11, 337-349.
74. Garnero P, Hausherr E, Chapuy MC, et al. (1996) Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11, 1531-1538.
75. Henriksen K, Leeming DJ, Christiansen C, et al. (2011) Use of bone turnover markers in clinical osteoporosis assessment in women: current issues and future options. Womens Health (Lond Engl) 7, 689-698.
76. Stepan J (2000) Prediction of bone loss in postmenopausal women. Osteoporos Int 11, Suppl. 6, 45-54.
77. Delmas P, Eastell R, Garnero P, et al. (2000) The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 11, Suppl. 6, S2-S17.
78. Garnero P & Delmas PD (2004) Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskelet Neuronal Interact 4, 50-63.
79. Garnero P, Sornay-Rendu E, Duboeuf F, et al. (1999) Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res 14, 1614-1621.
80. Delmas P (2000) Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int 11, Suppl. 6, S66-S76.
81. Delmas PD, Hardy P, Garnero P, et al. (2000) Monitoring individual response to hormone replacement therapy with bone markers. Bone 26, 553-560.
82. Rosen C, Chesnut CH & Mallinak NJ (1997) The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 82, 1904-1910.
83. Garnero P, Sornay-Rendu E, Claustrat B, et al. (2000) Biochemical markers of bone turnover, endogenous hormones and risk of fractures in postemenopausal women: the OFELY study. J Bone Miner Res 15, 1526-1536.
84. Ross PD, Kress BC, Parson RE, et al. (2000) Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int 11, 76-82.
85. van Daele P, Seibel M, Burger H, et al. (1996) Case-control analysis of bone resorption markers, disability and hip fracture: the Rotterdam Study. Br Med J 312, 482-483.
86. Gerdhem P, Ivaska KK, Alatalo SL, et al. (2004) Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 19, 386-393.
87. Meier C, Nguyen TV, Center JR, et al. (2005) Bone resorption and osteoporotic fractures in elderly men: the Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res 20, 579-587.
88. Bauer DC, Black DM, Garnero P, et al. (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19, 1250-1258.
89. Garnero P & Delmas PD (2006) Laboratory assessment of osteoporosis. In Dynamics of Bone and Cartilage Metabolism: Principles and Clinical Applications, 2nd ed., pp. 611-628 [M Seibel, S Robins and J Bilezikian, editors]. San Diego: Academic Press.
90. Johnell O, Odén A, De Laet C, et al. (2002) Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos Int 13, 523-526.
91. Bonnick SL & Shulman L (2006) Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med 119, S25-S31.
92. Briot K & Roux C (2005) What is the role of DXA, QUS and bone markers in fracture prediction, treatment allocation and monitoring? Best Pract Res Clin Rheumatol 19, 951-964.
93. Miller PD (2005) Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Curr Osteoporos Rep 3, 103-110.
94. Roux C, Garnero P, Thomas T, et al. (2005) Recommendations for monitoring antiresorptive therapies in postmenopausal osteoporosis. Joint Bone Spine 72, 26-31.
95. Garnero P, Shih WJ, Gineyts E, et al. (1994) Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79, 1693-1700.
96. Delmas PD (2000) How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis? Bone 27, 1-3.
97. Rosen C, Chesnut CHIII & Mallinak NJS (1997) The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 82, 1904-1910.
98. Greenspan SL, Resnick NM & Parker RA (2005) Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, doubleblind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 90, 2762-2767.
99. Ravn P, Hosking D, Thompson D, et al. (1999) Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84, 2363-2368.
100. Cummings SR, Karpf DB, Harris F, et al. (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112, 281-289.
101. Hochberg M (2000) Preventing fractures in postmenopausal women with osteoporosis: a review of recent controlled trials of antiresorptive agents. Drugs Aging 17, 317-330.
102. Hochberg MC, Greenspan S, Wasnich RD, et al. (2002) Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87, 1586-1592.
103. Wasnich RD & Miller P (2000) Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85, 231-236.
104. Watts NB, Geusens P, Barton IP, et al. (2005) Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res 20, 2097-2104.
105. Chapurlat RD, Palermo L, Ramsay P, et al. (2005) Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int 16, 842-848.
106. Heaney RP (2003) Is the paradigm shifting? Bone 33, 457-465.
107. Bjarnason NH, Sarkar S, Duong T, et al. (2001) Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12, 922-930.
108. Eastell R, Barton I, Hannon RA, et al. (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18, 1051-1056.
109. Reginster JY, Sarkar S, Zegels B, et al. (2004) Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34, 344-351.
110. Cranney A, Papaioannou A, Zytaruk N, et al. (2006) Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ 175, 52-59.
111. Hodsman A, Papaioannou A & Cranney A (2006) Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis. CMAJ 175, 48.
112. Kraenzlin ME & Meier C (2011) Parathyroid hormone analogues in the treatment of osteoporosis. Nat Rev Endocrinol 7, 647-656.
113. Bauer DC, Garnero P, Bilezikian JP, et al. (2006) Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 91, 1370-1375.
114. Chen P, Satterwhite JH, Licata AA, et al. (2005) Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20, 962-970.
115. Eastell R, Krege JH, Chen P, et al. (2006) Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 22, 61-66.
116. Lane NE, Sanchez S, Genant HK, et al. (2000) Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 11, 434-442.
117. Bergmann P, Body JJ, Boonen S, et al. (2009) Evidencebased guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract 63, 19-26.
118. Swiss Association against Osteoporosis (2010) Osteoporosis: prevention, diagnosis and treatment. Recommendation 2010. http://www.SVGO.ch
119. Manios Y, Moschonis G, Trovas G, et al. (2007) Changes in biochemical indexes of bone metabolism and bone mineral density after a 12-mo dietary intervention program: the Postmenopausal Health Study. Am J Clin Nutr 86, 781-789.
120. Bonjour JP, Brandolini-Bunlon M, Boirie Y, et al. (2008) Inhibition of bone turnover by milk intake in postmenopausal women. Br J Nutr 100, 866-874.
121. Bonjour JP, Benoit V, Rousseau B, et al. (2012) Consumption of vitamin D- and calcium-fortified soft white cheese lowers the biochemical marker of bone resorption TRAP 5b in postmenopausal women at moderate risk of osteoporosis fracture. J Nutr 142, 698-703.
122. Heaney RP, McCarron DA, Dawson-Hughes B, et al. (1999) Dietary changes favorably affect bone remodeling in older adults. J Am Diet Assoc 99, 1228-1233.
123. Palacios S, Castelo-Branco C, Cifuentes I, et al. (2005) Changes in bone turnover markers after calcium-enriched milk supplementation in healthy postmenopausal women: a randomized, double-blind, prospective clinical trial. Menopause 12, 63-68.
124. Manios Y, Moschonis G, Panagiotakos DB, et al. (2009) Changes in biochemical indices of bone metabolism in post-menopausal women following a dietary intervention with fortified dairy products. J Hum Nutr Diet 22, 156-165.
125. Heaney RP, Rafferty K & Dowell MS (2002) Effect of yogurt on a urinary marker of bone resorption in postmenopausal women. J Am Diet Assoc 102, 1672-1674.
126. Bonjour JP, Benoit V, Payen F, et al. (2013) Consumption of yogurts fortified in vitamin D and calcium reduces serum parathyroid hormone and markers of bone resorption: a double-blind randomized controlled trial in institutionalized elderly women. J Clin Endocrinol Metab 98, 2915-2921.
127. Bonjour JP, Benoit V, Pourchaire O, et al. (2009) Inhibition of markers of bone resorption by consumption of vitamin D and calcium-fortified soft plain cheese by institutionalised elderly women. Br J Nutr 102, 962-966.
128. Bonjour JP, Benoit V, Pourchaire O, et al. (2011) Nutritional approach for inhibiting bone resorption in institutionalized elderly women with vitamin D insufficiency and high prevalence of fracture. J Nutr Health Aging 15, 404-409.
129. Bonjour JP, Schurch MA & Rizzoli R (1996) Nutritional aspects of hip fractures. Bone 18, 139S-144S.
130. Chevalley T, Hoffmeyer P, Bonjour JP, et al. (2010) Early serum IGF-I response to oral protein supplements in elderly women with a recent hip fracture. Clin Nutr 29, 78-83.
131. Grinspoon S, Thomas E, Pitts S, et al. (2000) Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa. Ann Intern Med 133, 790-794.
132. Warren MP (2011) Endocrine manifestations of eating disorders. J Clin Endocrinol Metab 96, 333-343.
133. Soyka LA, Misra M, Frenchman A, et al. (2002) Abnormal bone mineral accrual in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 87, 4177-4185.
134. Dominguez J, Goodman L, Sen Gupta S, et al. (2007) Treatment of anorexia nervosa is associated with increases in bone mineral density, and recovery is a biphasic process involving both nutrition and return of menses. Am J Clin Nutr 86, 92-99.
135. Soyka LA, Grinspoon S, Levitsky LL, et al. (1999) The effects of anorexia nervosa on bone metabolism in female adolescents. J Clin Endocrinol Metab 84, 4489-4496.
136. Hotta M, Fukuda I, Sato K, et al. (2000) The relationship between bone turnover and body weight, serum insulinlike growth factor (IGF) I, and serum IGF-binding protein levels in patients with anorexia nervosa. J Clin Endocrinol Metab 85, 200-206.
137. Caillot-Augusseau A, Lafage-Proust MH, Margaillan P, et al. (2000) Weight gain reverses bone turnover and restores circadian variation of bone resorption in anorexic patients. Clin Endocrinol (Oxf) 52, 113-121.
138. Grinspoon S, Thomas L, Miller K, et al. (2002) Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. J Clin Endocrinol Metab 87, 2883-2891.
139. Bourrin S, Ammann P, Bonjour JP, et al. (2000) Dietary protein restriction lowers plasma insulin-like growth factor I (IGF-I), impairs cortical bone formation, and induces osteoblastic resistance to IGF-I in adult female rats. Endocrinology 141, 3149-3155.
140. Warren MP & Perlroth NE (2001) The effects of intense exercise on the female reproductive system. J Endocrinol 170, 3-11.
141. Gremion G, Rizzoli R, Slosman D, et al. (2001) Oligoamenorrheic long-distance runners may lose more bone in spine than in femur. Med Sci Sports Exerc 33, 15-21.
142. Warren MP, Brooks-Gunn J, Fox RP, et al. (2002) Osteopenia in exercise-associated amenorrhea using ballet dancers as a model: a longitudinal study. J Clin Endocrinol Metab 87, 3162-3168.
143. Ihle R & Loucks AB (2004) Dose-response relationships between energy availability and bone turnover in young exercising women. J Bone Miner Res 19, 1231-1240.
144. Misra M & Klibanski A (2011) The neuroendocrine basis of anorexia nervosa and its impact on bone metabolism. Neuroendocrinology 93, 65-73.
145. Shapses SA & Sukumar D (2012) Bone metabolism in obesity and weight loss. Annu Rev Nutr 32, 287-309.
146. Villalon KL, Gozansky WS, Van Pelt RE, et al. (2011) A losing battle: weight regain does not restore weight loss-induced bone loss in postmenopausal women. Obesity (Silver Spring) 19, 2345-2350.
147. Jensen LB, Kollerup G, Quaade F, et al. (2001) Bone minerals changes in obese women during a moderate weight loss with and without calcium supplementation. J Bone Miner Res 16, 141-147.
148. Ricci TA, Heymsfield SB, Pierson RN Jr, et al. (2001) Moderate energy restriction increases bone resorption in obese postmenopausal women. Am J Clin Nutr 73, 347-352.
149. Ricci TA, Chowdhury HA, Heymsfield SB, et al. (1998) Calcium supplementation suppresses bone turnover during weight reduction in postmenopausal women. J Bone Miner Res 13, 1045-1050.
150. Shapses SA, Von Thun NL, Heymsfield SB, et al. (2001) Bone turnover and density in obese premenopausal women during moderate weight loss and calcium supplementation. J Bone Miner Res 16, 1329-1336.
151. Riedt CS, Schlussel Y, von Thun N, et al. (2007) Premenopausal overweight women do not lose bone during moderate weight loss with adequate or higher calcium intake. Am J Clin Nutr 85, 972-980.
152. Bowen J, Noakes M & Clifton PM (2004) A high dairy protein, high-calcium diet minimizes bone turnover in overweight adults during weight loss. J Nutr 134, 568-573.
153. Thorpe MP, Jacobson EH, Layman DK, et al. (2008) A diet high in protein, dairy, and calcium attenuates bone loss over twelve months of weight loss and maintenance relative to a conventional high-carbohydrate diet in adults. J Nutr 138, 1096-1100.
154. Sukumar D, Ambia-Sobhan H, Zurfluh R, et al. (2011) Areal and volumetric bone mineral density and geometry at two levels of protein intake during caloric restriction: a randomized, controlled trial. J Bone Miner Res 26, 1339-1348.
155. Ryan AS, Nicklas BJ & Dennis KE (1998) Aerobic exercise maintains regional bone mineral density during weight loss in postmenopausal women. J Appl Physiol 84, 1305-1310.
156. Silverman NE, Nicklas BJ & Ryan AS(2009) Addition of aerobic exercise to a weight loss program increases BMD, with an associated reduction in inflammation in overweight postmenopausal women. Calcif Tissue Int 84, 257-265.
157. Josse AR & Phillips SM (2012) Impact of milk consumption and resistance training on body composition of female athletes. Med Sport Sci 59, 94-103.
158. Heaney RP, et al (2008) Design considerations for clinical investigations of osteoporosis. In Osteoporosis, 3rd ed., pp. 1598-1620 [M Marcus, D Feldman and DA Nelson, editors]. Amsterdam: Elsevier, Inc.
159. Heaney RP, et al (2008) Nutrition and risk for osteoprosis. In Osteoporosis, pp. 799-836 [M Marcus, D Feldman and DA Nelson, editors]. Amsterdam: Elsevier, Inc.
160. Mann JI (2010) Evidence-based nutrition: does it differ from evidence-based medicine? Ann Med 42, 475-486.
161. Bouxsein ML & Delmas PD (2008) Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res 23, 1155-1167.
162. Montori VM & Guyatt GH (2001) What is evidence-based medicine and why should it be practiced? Respir Care 46, 1201-1214.
163. Dawson B & Trapp RG (2001) Basic and Clinical Biostatistics, 3rd ed.. New York: Lange Medical Books/McGraw-Hill.
164. Mills EJ, Chan AW, Wu P, et al. (2009) Design, analysis, and presentation of crossover trials. Trials 10, 27.
165. Iglehart JK (2009) Prioritizing comparative-effectiveness research - IOMrecommendations.NEngl JMed 361, 325-328.
166. Kaats GR, Preuss HG & Leckie RB (2009) Comparative effectiveness research (CER): opportunities and challenges for the nutritional industry. J Am Coll Nutr 28, 234-237.
167. Kaats GR, Preuss HG, Croft HA, et al. (2011) A comparative effectiveness study of bone density changes in women over 40 following three bone health plans containing variations of the same novel plant-sourced calcium. Int J Med Sci 8, 180-191.
168. Michalek JE, Preuss HG, Croft HA, et al. (2011) Changes in total body bone mineral density following a common bone health plan with two versions of a unique bone health supplement: a comparative effectiveness research study. Nutr J 10, 32.